About Acepix Biosciences
Acepix Biosciences develops research products and services for biomarker discovery, translational research and histopathology, supporting pharmaceutical, biotechnology and academic research programmes. The company focuses on protein biology, tissue-based analysis and cell-based research, combining expertise in biospecimen preparation, pathology workflows and biomarker evaluation. Its capabilities enable researchers to investigate disease mechanisms, validate biomarkers and assess assay performance using well-characterised biological materials and pathology-based analytical approaches. Through proprietary technologies and access to global biobank networks, Acepix Biosciences provides standardised reference materials and research specimens for preclinical and translational studies.
The company’s portfolio includes A-FLX™ Cell Pellets, FFPE and frozen cell pellet controls, high-quality FFPE human tissues, animal tissues and tissue arrays designed for assay development, biomarker validation and quality control applications. Acepix also offers histology, digital pathology and AI-supported image analysis services, alongside cell-based products and research services covering a broad range of cell lines. These products and services support immunohistochemistry (IHC), tissue biomarker studies, pathology-based assay development and translational research workflows.
Europa Biosite subsidiaries distribute Acepix Biosciences products across Austria, Belgium, Canada, Denmark, Estonia, Finland, Germany, Iceland, Ireland, Latvia, Lithuania, Luxembourg, Netherlands, Norway, Sweden, Switzerland, United Kingdom and USA.